How has the ADVISE trial changed your approach to steroid sparing agents for non-infectious uveitis?

The ADVISE trial was a well-designed, multinational trial that compared adalimumab therapy for non-infectious, intermediate, posterior or panuveitis versus conventional immunosuppressive therapy or CID. Two hundred twenty-seven subjects were enrolled over four years, and a fifth year was required to...